| Series Title | European Voice |
|---|---|
| Series Details | Vol.9, No.20, 29.5.03, p4 |
| Publication Date | 28/05/2003 |
| Content Type | News |
|
Date: 28/05/03 MEMBER states have been asked to investigate the potentially fatal side effects of a painkiller which is increasingly being used throughout the EU. Use of Dextropropoxyphene (DXP) is already restricted in Sweden where medical studies show that 1,592 people died in 1992-1999 after taking the drug. Used in medicines such as Antalvic and Distalgesic, the drug is becoming increasingly popular in other EU countries, notably France and the UK, a trend described as "worrying" by Swedish Liberal MEP Marit Paulsen. The Parliament's environment committee was told last week that the Commission will now ask all member states to compile reports on the side effects of DXP by this September. "I'm pleased that this important issue is now on the EU agenda and that the competent authorities in the respective member states now have to deal with it," said Paulsen. |
|
| Subject Categories | Health |
